In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot® ) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study

Haemophilia. 2022 Sep;28(5):e149-e152. doi: 10.1111/hae.14650. Epub 2022 Aug 10.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Bispecific* / pharmacology
  • Antibodies, Bispecific* / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Factor VIII / therapeutic use
  • Factor VIIa
  • Hemophilia A* / drug therapy
  • Humans
  • Pilot Projects

Substances

  • Antibodies, Bispecific
  • Antibodies, Monoclonal, Humanized
  • emicizumab
  • Factor VIII
  • Factor VIIa

Supplementary concepts

  • Factor 8 deficiency, acquired